⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

October 19, 2021

Study Completion Date

July 18, 2022

Conditions
Positron-Emission TomographyMetastatic Solid Tumors
Interventions
DRUG

⁸⁹Zr-Df-IAB22M2C

⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)

Trial Locations (15)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Perelman School of Medicine, Philadelphia

35294

University of Alabama-Birmingham Hospital, Birmingham

48201

Karmanos Cancer Institute, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa City

63110

Washington University School of Medicine, St Louis

72205

CARTI Cancer Center, Little Rock

90033

Keck Hospital of USC, Los Angeles

LAC + USC Medical Center, Los Angeles

USC/Norris Comprehensive Cancer Center, Los Angeles

90404

John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica

91010

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

98109

Seattle Cancer Care Alliance/ University of Washington, Seattle

02215

Dana-Farber Cancer Institute (DFCI), Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ImaginAb, Inc.

INDUSTRY